-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on AtriCure, Raises Price Target to $64

Benzinga·09/02/2026 10:02:21
Listen to the news
Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $45 to $64.